Search tips
Search criteria 


Logo of scirepAboutEditorial BoardFor AuthorsScientific Reports
Sci Rep. 2017; 7: 43535.
Published online 2017 March 6. doi:  10.1038/srep43535
PMCID: PMC5337933

Notch Ligand DLL4 Alleviates Allergic Airway Inflammation via Induction of a Homeostatic Regulatory Pathway


Notch is a pleiotropic signaling family that has been implicated in pathogenesis of allergic airway diseases; however, the distinct function of individual Notch ligands remains elusive. We investigated whether Notch ligands, Jagged1 and DLL4, exert differential effects in OVA-induced allergic asthma. We found that whilst Jagged1 inhibition mitigated Th2-dominated airway inflammation, blockage of DLL4 aggravated the Th2-mediated asthma phenotypes. Additionally, Jagged1 signaling blockage enhanced IL-17 production and neutrophilic airway infiltration. In vitro, exogenous Jagged1 induced Th2-skewed responses, whereas augmented DLL4 signaling displayed a dual role by promoting expansion of both Tregs and Th17. In vivo, DLL4 blockage impaired Treg differentiation which plausibly resulted in exaggerated asthma phenotypes. On the contrary, administration of DLL4-expressing antigen-presenting cells promoted endogenous Treg expansion and ameliorated the allergic responses. Therefore, whilst Jagged1 induces Th2-skewed inflammation, DLL4 elicits an essential self-regulatory mechanism via Treg-mediated pathway that counterbalances Jagged1-induced Th2 responses and facilitates resolution of the airway inflammation to restore homeostasis. These findings uncover a disparate function of Jagged1 and DLL4 in allergic airway diseases, hinting feasibility of Notch ligand-specific targeting in therapy of allergic airway diseases.

Allergic asthma is characterized by recurrent inflammatory episodes of the airways towards harmless environmental factors. The resulting pathological changes of mucus metaplasia, increased subepithelial matrix deposition, and airway smooth muscle hypertrophy/hyperplasia cumulatively lead to airway hyperresponsiveness, irreversible airway remodelling and obstruction1,2. In addition to being a genetically predisposed disease3, allergic asthma has long been regarded as a Th2-skewed immune reaction causally attributed to insufficient Treg immune regulation4,5 and re-introduction of Tregs into asthmatic animals was able to suppress the allergic responses and revert the asthma phenotypes6,7,8.

The mammalian Notch family includes four Notch receptors, Notch-1, -2, -3 and -4 and five Notch ligands, Jagged-1, -2, and Delta-like (DLL)-1, -3 and -4. Upon ligand binding of the Notch, proteolytic cleavage of the transmembrane domain by γ-secretases releases the intracellular domain (NICD), which subsequently translocates into the nucleus to bind to the PBPJκ/CSL and together with the proteins of the Mastermind-like family, forms the transcriptional activation complex for the downstream target genes such as the HES family9. Among its pleiotropic functions in development and tissue renewal, Notch has been shown to regulate differentiation of literally almost all T-helper (Th) subsets, including Th1, Th2, Th9, Th17 and regulatory T cells (Tregs) via the induction of lineage-specific transcription factors as well as the signature products of distinct T-cell lineages10,11. However, with the common downstream canonical signaling events irrespective of individual Notch receptor-ligand pairs, how does Notch do it all? There are studies proposing a context-dependent mechanism wherein Notch acts as a signaling hub to integrate additional signals originated from the adjacent milieu, such as those derived from membrane receptors and cytokines. Alternatively, studies have also showed that engagement of distinct Notch ligands elicits signals differentially skewing Th subset differentiation. In this theory, ligand-specific signaling outcome is conceivably orchestrated by characteristic expression pattern of individual Notch family members under distinct inflammatory circumstances. The latter proposition undoubtedly lays the basis for therapeutic approaches exploiting ligand-specific targeting of Notch signaling pathway. In support of this theory, gain-of-function studies have showed that while DLL engagement induces Th1 differentiation, Jagged generates signals that favor the alternate Th2 fates12,13,14.

γ-Secretase inhibitors (GSI) are non-specific inhibitors of Notch signaling pathway. Clinical trials and experimental studies in various cancers and immune-mediated diseases have shown a therapeutic potential of GSI. In experimental allergic airway diseases, administration of GSI caused a general suppression of the asthma phenotypes15. In addition, GSI-treated CD4+ or CD8+ T cells failed to restore airway inflammation in IL-4- or CD8-deficient mice, or to enhance the responses in WT mice16,17. Nevertheless, non-specific suppression of Notch may cause unfavorable outcomes considering the pleiotropic functions that have been attributed to Notch in various biological processes. The potential drawbacks in this concern together with studies that showed a more effective modification of Notch signaling by using receptor/ligand-specific approaches support therapeutic advantages of specific Notch targeting18.

In this study, we investigated the distinct role of Jagged1 vs DLL4 in allergic airway diseases by using the OVA-induced murine asthma model. We found that whilst Jagged1 contributed to allergic Th2 responses, DLL4 counteracted the Th2 responses via the induction of endogenous Treg-mediated regulatory pathway which conceivably constitutes an inducible and essential homeostatic mechanism during allergic airway inflammation.


Upregulated Notch expression during allergic airway inflammation

To investigate the distinct role of Notch in pathogenesis of allergic airway diseases, expression profile of Notch in pulmonary leukocytes was examined. We found that OVA-sensitization alone induced expression of Notch1, Notch2 and Notch3 in pulmonary CD4+ T cells compared to PBS treatment. The enhanced expression pattern of the Notch receptors in CD4+ T cells of the OVA-sensitized mice was further upregulated after aerosol OVA challenge (Fig. 1A). In parallel, OVA sensitization induced the expression of Jagged1, DLL4 and, to a lesser extent, Jagged2 in pulmonary CD11c+DCs. After aerosol OVA challenge, the DC populations expressing Jagged1, Jagged2 and, much more prominently, DLL4 were further increased (Fig. 1B). On the contrary, CD11c+ alveolar macrophages expressed only low levels of Notch ligands despite OVA challenge, indicating DCs as the main expressers of Notch ligands and the key player in pathogenesis of allergic airway diseases.

Figure 1
Allergen sensitization and challenge enhanced expression of Notch receptors and ligands in infiltrated pulmonary leukocytes.

The expression profile of the Notch family components in splenic CD4+ T cells and CD11c+DCs was also examined (Fig. 1C). In contrast to their lung-infiltrating counterparts, splenic CD4+ T cells showed comparable expression of the Notch receptors despite OVA sensitization and challenge compared to PBS controls, whereas OVA treatment moderately increased the Jagged1- and DLL4-expressing DC populations of the spleens.

DLL4 and Jagged1 signaling blockage leads to different asthma phenotypes

To investigate the differential effects of Jagged1 and DLL4 in allergic airway inflammation, selective blockage of Jagged1 and DLL4 was conducted by treating the mice with Jagged1- and DLL4-specific blocking Abs along the course of OVA sensitization/challenge (Fig. 2A). The blocking effect of the Abs was confirmed by decreased NICD expression in both the nuclear and cytoplasmic lysates of stimulated splenic T cells (Fig. 2B). The protocol with Abs administered both before OVA sensitization and challenge was adopted since we observed only a lesser or marginal effect when Abs were given solely before sensitization or challenge. In our OVA-induced murine asthma model, OVA sensitization induced the production of OVA-specific IgE and a Th2-skewed IgG subclass profile wherein the levels of IgG1 prevailed that of IgG2a (Fig. 2C). In mice treated with DLL4 blocking Ab, OVA-specific IgE and the Th2-skewed IgG profile were even more enhanced compared to control Ig-treated OVA mice. In contrast, Jagged1 blockage significantly mitigated the characteristic IgE and IgG Ab profile.

Figure 2
Differential regulation of asthma phenotypes by DLL4 and Jagged1.

Histologic studies of the lungs showed significantly increased cell infiltration in DLL4 Ab-treated mice compared to Ig- and Jagged1 Ab-treated mice (Fig. 2D). However, whilst blockage of Jagged1 signaling alleviated the induction of OVA-specific Ab profile, lung histology of these mice displayed comparable leukocyte infiltration as the Ig-treated controls, implying disparate effects of Jagged1-derived signals in allergen-induced Ab production and leukocyte recruitment. In accordance with the histologic findings, DLL4 Ab-treated mice exhibited significantly increased BALF infiltrates of monocyte, eosinophils and lymphocytes compared to their Ig- and Jagged1 Ab-treated counterparts (Fig. 2E). On the other hand, although blockage of Jagged1 hampered eosinophil recruitment into the lungs, neutrophil infiltration in these mice was significantly increased. Therefore, the comparable leukocyte infiltration between Jagged1Ab-treated mice and Ig-treated controls, as observed in histologic studies, was composed of different leukocyte populations. Decreased BALF eosinophils after Jagged1 blockage was somehow compensated by increased neutrophil trafficking, whilst the lack of DLL4 signals elicited the opposite effects by enhancing eosinophil recruitment but not neutrophil trafficking.

Airway hyperresponsiveness of these mice were accessed by challenging the mice with escalating concentrations of aerosol methacholine (Fig. 2F). As can be expected, Ig-treated OVA mice displayed prompt and increased airway responsiveness to methacholine compared to PBS controls. In mice treated with DLL4 Ab, airway hyperresponsiveness was significantly aggravated. In contrast, inhibition of Jagged1 improved airway hyperresponsiveness to levels of the PBS controls. It is noteworthy that severe bronchospasm developed in ~30–40% of the mice treated with DLL4 Ab, which led to mortality of these mice during the process of methacholine challenge. The aggravated asthma phenotypes after DLL4 blockage suggest probable beneficial effects of DLL4 during allergic airway inflammation.

DLL4 and Jagged1 orchestrate divergent cytokine secretion in allergic airway diseases

BALF collected after OVA challenge was examined for cytokine expression (Fig. 3A). Increased IFN-γ, IL-5 and, at lower levels, IL-17 were found in BALF of essentially all OVA-treated mice compared to PBS controls. In Notch-ligand blockage groups, whilst DLL4 blockage selectively enhanced IL-5 production, inhibition of Jagged1 resulted in decreased IL-5 and increased IL-17 secretion compared to the other two treatments. These findings indicate divergent functions of DLL4 and Jagged1 in the progression of allergic airway inflammation. In addition, cytokine secretion was also examined after OVA re-stimulation of the splenocytes (Fig. 3B). Similar to what was found in BALF, splenocytes isolated from DLL4 Ab-treated mice selectively produced more IL-5, whereas splenocytes of the Jagged1 blockage group exhibited decreased IL-5 and enhanced IL-17 secretion.

Figure 3
Blockage of DLL4 signaling enhanced Th2-inflammation whereas Jagged1 signaling blockage released IL-17 response.

Based on the above findings and previous literatures, we speculated a counterbalanced effect of Jagged1 and DLL4 in pathogenesis of allergic airway diseases. Whilst Jagged1-derived signals are known to preferentially induce Th2 responses, DLL4 has been shown to induce Th17 responses. Therefore, blockage of either Jagged1 or DLL4 would likely unleash the effects of the opposite pathway. To this aspect in our current study, inhibition of DLL4 will provide permissive conditions for Jagged1 signaling that cumulated in aggravated and, in one third of the mice, lethal allergic airway inflammation. However, based on our current results thus far, the “counterbalancing” theory could not fully explain the seemingly paradoxical results on neutrophilic airway inflammation, as can be induced by DLL4-elicited IL-17, and the otherwise mitigated asthma phenotypes after Jagged1signaling blockage. It is possible that other operational mechanisms derived from DLL4 after inhibition of Jagged1 are as yet unidentified and it is our interests to explore in this study.

DLL4 and Jagged1 exert differential regulation of Th subset differentiation

To delineate further the effector mechanisms of DLL4 and Jagged1 signaling, we performed a series of in vitro studies wherein CD4+ T cells were stimulated in the presence of Jagged1 and DLL4 recombinant proteins. The additive effect of the Jagged1 and DLL4 proteins was verified by increased NICD expression of the stimulated splenocytes (Fig. 4A). Gene expression of key Th subset transcription factors was analyzed after 48-hr stimulation (Fig. 4B). The data showed comparable T-bet expression irrespective of the status of Jagged1 or DLL4 signaling; nonetheless, Gata3 was induced by augmented Jagged1 but not DLL4 signaling. In addition, whilst RORc expression was significantly increased by addition of DLL4, augmented DLL4 signaling also enhanced FoxP3 expression, suggesting a dual role of DLL4 in Th subset differentiation. The particular Th subtypes as regulated by exogenous Jagged1 and DLL4 were also analyzed by intracellular cytokine staining (Fig. 4C). In accordance with the results of Th subset transcription factors, Jagged1-derived signals selectively induced IL-4-secreting Th-cells. On the other hand, DLL4 promoted both IL-17- as well as IL10-secreting Th-cells. Collectively, the in vitro data demonstrated a Th2-promoting function of Jagged1 and a dual effect of DLL4-derived signals in Th17 and Treg-cell differentiation.

Figure 4
DLL4 and Jagged1 exerted distinct regulation on Th subset development.

These findings not only support our speculation that Jagged1 and DLL4 generated mutually counterbalanced signals, they also prompted that the aggravated asthma severity after DLL4 blockage can be attributed to the DLL4-elicited regulatory pathway that prevails the Th17-mediated inflammation in the asthma model.

DLL4 induces expansion of endogenous Tregs and ameliorates allergic airway inflammation

The necessity of DLL4 in immune suppressive function of Tregs was investigated by antigen-stimulated proliferation assay which showed that blockage of DLL4 did not affect the immune suppressive function of Tregs, and neither did Jagged1 blockage (Fig. 5A). The role of DLL4 in endogenous Treg induction was next envisaged in the murine asthma model (Fig. 5B). We found that pulmonary Tregs was significantly increased in asthmatic mice compared to PBS controls. In the setting of DLL4 blockage, Treg population was significantly diminished; however, the lack of Jagged1 signals resulted in enhanced Treg expansion. Therefore, exacerbation of the allergic responses after blockage of DLL4 was not due to impaired Treg immune suppression, but was attributed to insufficient Treg differentiation.

Figure 5
DLL4 induced endogenous Tregs during allergic airway inflammation.

Whilst kindred of inflammatory leukocytes cooperated to propagate the inflammatory response, induction of endogenous Tregs and/or recruitment of Tregs into the lungs worked simultaneously alongside the progression of allergic inflammation. We speculated that the emergence of endogenous Treg population in the lungs during allergic airway inflammation constituted an inducible homeostatic mechanism to resolve the allergic responses and inadequate induction of this regulatory population would hence lead to aggravated pathology.

To verify the in vivo regulatory effect of DLL4, mice were given DLL4-overexpressing Raw-DLL4 before OVA sensitization and challenge (Fig. 5C). Raw-DLL4 cells can be detected in the lung as early as 30 min after transfer and trafficking of the Raw-DLL4 into the lungs continued when observed at 2 hr (Fig. 5D). BALF Tregs analyzed after OVA challenge showed a significant induction of Tregs after Raw-DLL4 transfer (Fig. 5E). The OVA-specific IgE and Th2-IgG profile was improved in mice receiving Raw-DLL4 transfer compared to OVA mice receiving Raw-Ctrl (Fig. 6A). Additionally, eosinophilic airway infiltration and airway hyperresponsiveness were both ameliorated after Raw-DLL4 transfer (Fig. 6B,C). Noticeably, BALF neutrophils were also decreased after Raw-DLL4 transfer. Cytokine profile in BALF and spleen demonstrated concordant results; whilst expression of IL-5 and IL-17 were decreased in Raw-DLL4-transferred mice, IL-10 production was increased (Fig. 6D). The potential detrimental effects of IL-17 production and neutrophilic airway trafficking, as can be induced by DLL4, were not evoked by Raw-DLL4 transfer, supporting a dominant role of DLL4-mediated Treg induction in vivo. Collectively, these data support a Treg-dependent immune regulatory role of DLL4 in allergic airway diseases.

Figure 6
DLL4 ameliorated allergic airway inflammation.


Our study demonstrated the divergent functions of Jagged1 and DLL4 in pathogenesis of allergic airway inflammation. Whilst Jagged1 signaling blockage mitigated the Th2-dominated allergic responses, inhibition of DLL4 exaggerated the allergic phenotypes. We found that DLL4-derived signals ameliorated the allergic responses via induction of Treg-mediated regulatory pathway. It is worth noting that DLL4 also promoted Th17 differentiation; however, in the murine asthma model, Treg-mediated immune regulation, as induced by DLL4, overcame Th17-mediated inflammation, which conceivably led to aggravated allergic phenotypes after DLL4 blockage. It is plausible that allergic inflammation simultaneously generates homeostatic self-regulatory cues upon which DLL4 responses with signals favoring Treg differentiation over Th17. This speculation was supported by the findings that DLL4-overexpressing APCs enhanced Treg expansion and ameliorated the allergic pathology.

Although Notch is implicated in the differentiation program of all known Th subsets, there has been no consensus regarding the exact operation mechanisms that can be ascribed to explain how the various Notch family members are selectively called into effects in these diverse and often mutually exclusive processes. The signaling competence of unique Notch receptor-ligand pairs has been shown to be regulated by Fringe-mediated glycosylation in the Golgi19,20. Therefore, Notch receptors can be modulated to deliver signals selectively from particular ligands but not others before ligand-binding on the cell surface. Notch can also be activated following TCR stimulation without ligand engagement, albeit through yet unknown mechanisms21. These activation characteristics provide an operation mechanism for Notch to exert their effects in response to environmental cues during inflammation. Previous studies have reported a role for Jagged in promoting Th2-cell differentiation and inflammation16,22. However, in our current study, Jagged1 inhibition did not completely abrogate the allergic phenotypes but mitigated the intensity of the allergic responses. It is plausible that other molecules and signaling family operated in companion of Notch-Jagged1 in pathogenesis of allergic airway diseases. Therefore, Notch-Jagged1 signaling pair reacts in response to or in coordination with the environmental cues to modulate the overall inflammatory response. Nonetheless, it is also conceivable that Jagged2 molecule may also play a role despite the expression levels of Jagged2 in pulmonary leukocytes were extremely low in our current study.

On the other hand, DLL has been shown to generate signals that antagonize Jagged-induced Th2 inflammation23. In line with these findings, DLL4 was demonstrated to tune-down allergic airway inflammation by inducing Th2-cell apoptosis24 and administration of DLL1-Fc protein was shown to prevent allergic airway responsiveness by skewing the Th2 response to a Th1 phenotype17. In addition, the protective Th1-cell response to respiratory syncytial virus infection was switched to Th2-mediated allergic responses after inhibition of DLL4 signals25. Adding to the counterbalancing effects of the Jagged and DLL, our studies demonstrated an aggravated allergic phenotype after DLL4 inhibition that was attributed to insufficient Treg differentiation in the absence of DLL4 signals. Therefore, although Notch exerts function in a context-dependent manner, there is also the existence of ligand-specific functions that can be exploited for therapies of allergic airway diseases. It is conceivable that differential utilization of Notch ligands operates as a mechanism orchestrating the nature and extent of the immune activation vs regulation.

Notch has been shown to induce IL-10 production in established Th1 cells as an essential mechanism for self-regulation of Th1 immunity. In these studies, whilst IL-10 can be elicited by all four Notch receptors, the response was exclusively triggered by DLL4 but not Jagged26. On the role of DLL4 in Treg differentiation, our data have been contradictory to previous studies of different disease models. In experimental allergic encephalomyelitis, type 1 diabetes and graft-versus-host disease models, blockage of DLL4 was demonstrated to ameliorate disease severity through induction of Tregs27,28,29. In addition, whilst Tregs preferentially expressed Notch-3, -4 and Jagged1, DLL1 and DLL430,31,32, Treg differentiation was induced following Notch3 activation and Jagged engagement33,34,35. The discrepancy can partly be reconciled by the context-dependent operation characteristic that orchestrates the overall outcome of Notch signaling; i.e. Th1/Th17-mediated pathologies induced by DLL4 in these disease models vs Th2-skewed responses attributed to Jagged1 in our asthma model.

The application of GSI to target Notch for deranged cell growth in various cancers has met some success in several clinical trials. It is expectable that manipulation of Notch signaling in immunologic compartments can be exploited to treat allergic airway diseases. Considering the functions of Notch in a plethora of biological processes and hence the potential side-effects derived from non-selective targeting, ligand-specific approaches pose an attractive and safer therapeutic strategy. To this aspect, inducing endogenous Tregs through DLL4 signaling will be applicable to prevention and resolution of allergic airway inflammation.



DO11.10 mice carrying an OVA323–339-specific TCR transgene and BALB/c mice were both purchased from the Jackson Laboratory (Bar Harbor, Maine, USA) and bred in the National Taiwan University animal facility under SPF conditions. Animal procedures were reviewed and approved by the National Taiwan University Animal Ethics Committee. All methods were performed in accordance with the relevant guidelines and regulations.

OVA-induced allergic airway inflammation

6 w/o female BALB/c mice were sensitized by two i.p. injections of 50 and 20 μg OVA (Grade V; Sigma-Aldrich, St. Louis, MO) emulsified in 1% alum (Pierce Biotech, Rockford, IL, USA) on day (D) 0 and D12, followed by 30-min aerosol OVA (5%) challenge for three consecutive days since D19. In indicated groups, mice were given anti-DLL4 or anti-Jagged1 blocking Ab (10 mg/kg; BioXCell, NH, USA) or DLL4-expressing APCs (Raw-DLL4, 1.5 × 106 cells/mouse) via tail vein 1 h before sensitization and challenge. OVA-sensitized mice receiving a hamster IgG isotype control Ab (Ig) or control APCs (Raw-Ctrl) were used as positive controls, whereas mice receiving PBS treatment were negative controls.

Measurements of antibodies and cytokines

Serum OVA-specific Ab and cytokines in BALF and culture supernatants were measured by ELISA following manufacturer’s instruction (R&D systems and BioLegend) as previously described38.

Bronchoalveolar lavage fluid (BALF) and differential leukocyte counts

Leukocytes in the BALF were pelleted and resuspended for cytospins (Shandon Cytospin 2; Thermo Scientific, MA, USA), followed by staining with Giemsa and May-Grünwald (Sigma-Aldrich). Differential leukocyte counts with a total cell count of 500 per cytospin were enumerated in a blinded fashion.

Measurement of airway hyperresponsiveness (AHR)

Mice were anaesthetized and exposed to escalating concentrations of methacholine (0~60 mg/mL, Sigma-Aldrich) via a tracheal cannula and airway resistance was recorded by using the Buxco Pulmonary Mechanics System (Buxco Electronics, NC, USA). Lung resistance (cmH2O*Sec/mL) at individual methacholine concentration was recorded and compared with that of PBS after substracting baseline resistance.

Isolation and characterization of pulmonary leukocytes

After PBS perfusion to expel intravascular blood content, the lungs were excised and minced, followed by digestion with 1 mg/mL collagenase IV and 0.5 mg/mL DNase I (Sigma-Aldrich) at 37 °C for 30 min. After digestion, the released leukocytes were resuspended in HBSS and centrifuged over 60% Percoll gradient (GE Healthcare, IL, USA) at 3200 rpm for 20 min. Leukocytes were collected from the Percoll/HBSS interface. Notch expression profile and Treg population were analyzed by FACS.

Establishment of DLL4-overexpressing APC lines

Raw264.7 cells were grown to 80% confluence in 6-well plates before transfected with 2 μg pcDNA3.1-DLL4-Flag (Raw-DLL4), or pcDNA3.1-Flag empty vector (Raw-Ctrl) (GenScript, NJ, USA) by using Turbofect transfection reagents (Thermo-Scientific). At day 2 after transfection, culture media was replaced by G418-containing 10% DMEM (0.5 g/L, Invitrogen). G418-resistant clones were selected by limiting dilution in 96-well plates and expanded when reached confluent. For in vivo tracing of the transferred APCs, DLL4-overexpressing Raw cells were further transduced with pAS2-EGFP or pLKO-AS2 control pseudoviral particles (RNAiCore, Academia Sinica, TW), followed by selection with puromycin (2 μg/ml, Invitrogen). GFP-expressing Raw-DLL4 cells were examined by FACS or visualized by tissue immunostaining against GFP (Abcam, Cambridge, UK).

Evaluation of Notch ligand-specific immune function

Splenic CD4+ T cells were isolated from DO11.10 mice by using magnetic bead-conjugated Ab per manufacturer’s negative selection protocol (Miltenyi, Bergisch Gladbach, Germany). 2 × 106 CD4+ T cells were co-cultured with irradiated syngeneic APCs in the presence of OVA323–339 peptide (2.5 μg/mL). When indicated, Jagged1-Fc and DLL4-Fc recombinant proteins (10 μg/mL, R&D, Minneapolis, USA) were pre-coated onto 48-well plates at 4 °C for overnight before coculture. At 48 hr in culture, RNA lysate was collected for gene expression. Alternatively, cells were restimulated at 48 hr with PMA (100 ng/mL, Sigma-Aldrich), ionomycine (1 μg/mL) plus monesin for 6 hrs. Intracellular cytokine expression was detected by FACS.

Evaluation for the efficacy of DLL4- and Jagged1-specific reagents

To validate the function of DLL4- and Jagged1-specific blocking Ab and recombinant proteins in modulating Notch signaling, splenocytes isolated from OVA-sensitized BALB/c mice were stimulated with 200 μg/mL OVA. When indicated, the stimulation was performed in the presence of anti-DLL4 or anti-Jagged1 Ab at 10 and 20 μg/mL (BioXCell); hamster IgG isotype Ab was used as the control. In parallel, Jagged1-Fc and DLL4-Fc recombinant proteins (10 μg/mL, R&D, Minneapolis, USA) were pre-coated onto 48-well tissue culture plates at 4 °C for overnight before the stimulation. At 16 hr in culture, protein lysates were collected for NICD Western blotting.

Proliferation assay

CD4+CD25+ Tregs and CD4+CD25- effector T cells (Teff) were isolated from the spleens of DO11.10 mice by using the MACS Treg-cell negative isolation kit (Miltenyi Biotech) as per manufacturer’s instructions. T cells (5 × 104) and irradiated APCs (1 × 105) also isolated from DO11.10 mice were co-incubated with 200 μg/mL OVA and pulsed with 1 μCi of 3H at 72 hr. 3H incorporation was quantified 16 hrs later by using an automated multi-sample harvester and dry scintillation counter (Packard Instrument Co., Meridan, CT, USA). Data compared against un-stimulated cells were expressed as stimulation index (S.I.). When indicated, the stimulation was performed in the presence of anti-DLL4 or anti-Jagged1 Ab (20 μg/mL, BioXCell).

Quantitative real-time PCR

For gene expression, cDNA was synthesized by RT-PCR and gene expression was amplified by sequence-matched primer pairs (Table 1) and SYBR Supermix (Roche, NJ, USA) in an Applied Biosystems 7900 real-time PCR system (San Francisco, CA, USA). The data was normalized with the expression of GAPDH or cyclophilin.

Table 1
Primer sequences.

Flow cytometry

Cells were incubated with fluorescence-conjugated Ab or isotype-matched control Ab for 30 min at 4 °C. For intracellualr cytokine staining, cells finishing surface staining were fixed with 4% paraformaldehyde and permeabilized by 0.1% saponin in PBS before cytokine staining. The samples were analyzed with a flow cytometer and CellQuest software (FACScalibur, BD, San Jose, CA). Fluorescence-conjugated antibodies were purchased from eBioscience and BioLegend (San Diego, CA, USA.)

Western blotting

Cytoplasmic and nuclear proteins were extracted by using the NE-PER extraction reagents as per manufacturer’s protocol (Thermo Scientific). The extracted proteins were separated on 8% gels by SDS-PAGE, transferred onto PVDF membranes (EMD Millipore, MA, USA), and followed by sequential incubation with an primary Ab against Notch intracellular domain (NICD, Cell Signaling, MA, USA) and an HRP-conjugated secondary Ab. Lamin B and GAPDH (Upstate, New York, USA) were used as internal controls for nuclear and cytoplasmic proteins, respectively. Blots were detected by using ECL Plus (Amersham Pharmacia, NJ, USA). Integrated band density was measured by Alpha Innotech Chemilmager 5500 (Alpha Innotech, CA, USA).

Statistical analysis

Data were expressed as Mean ± SD. Statistical comparisons between groups were made by one-way ANOVA, or unpaired t-test by using GraphPad Prism 5 Software. A P value of less than 0.05 was considered as statistically significant.

Additional Information

How to cite this article: Huang, M.-T. et al. Notch Ligand DLL4 Alleviates Allergic Airway Inflammation via Induction of a Homeostatic Regulatory Pathway. Sci. Rep. 7, 43535; doi: 10.1038/srep43535 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supplementary Information:


We are grateful for the funding of this project from the Ministry of Science and Technology, Taiwan (NSC99-2314-B-002-022-MY3) and National Taiwan University Hospital (NTUH 105-04, NTUH 106-S3546).


The authors declare no competing financial interests.

Author Contributions M.-T.H. designed the study, performed experiments, interpreted data & writing the paper, Y.-L.C., C.-I.L., and W.-L.L. performed the experiments & analyzed the data, L.-C.H. and H.Y. gave advice on the project and provided key reagents, B-L.C. gave conceptual advice, interpreted data & wrote the paper.


  • Fahy J. V. Type 2 inflammation in asthma - present in most, absent in many. Nat Rev Immunol 15, 57–65 (2015). [PMC free article] [PubMed]
  • Lambrecht B. N. & Hammad H. The immunology of asthma. Nat Immunol 16, 45–56 (2015). [PubMed]
  • Vahedi G., Richard A. C. & O’Shea J. J. Enhancing the understanding of asthma. Nat Immunol 15, 701–703 (2014). [PMC free article] [PubMed]
  • Umetsu D. T., McIntire J. J., Akbari O., Macaubas C. & DeKruyff R. H. Asthma: an epidemic of dysregulated immunity. Nat Immunol 3, 715–720 (2002). [PubMed]
  • Strickland D. H. et al. . Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol 4, 43–52 (2011). [PubMed]
  • Kearley J., Barker J. E., Robinson D. S. & Lloyd C. M. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J. Exp. Med. 202, 1539–1547 (2005). [PMC free article] [PubMed]
  • Lewkowich I. P. et al. . CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J. Exp. Med. 202, 1549–1561 (2005). [PMC free article] [PubMed]
  • Strickland D. H. et al. . Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+CD25+ regulatory T cells. J. Exp. Med. 203, 2649–2660 (2006). [PMC free article] [PubMed]
  • Tanigaki K. & Honjo T. Regulation of lymphocyte development by Notch signaling. Nat Immunol 8, 451–456 (2007). [PubMed]
  • Ito T., Connett J. M., Kunkel S. L. & Matsukawa A. Notch system in the linkage of innate and adaptive immunity. J Leukoc Biol 92, 59–65 (2012). [PubMed]
  • Amsen D., Helbig C. & Backer R. A. Notch in T cell differentiation: All things considered. Trends in Immunology 36, 802–814 (2015). [PubMed]
  • Maekawa Y. et al. . Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity 19, 549–559 (2003). [PubMed]
  • Amsen D. et al. . Instruction of distinct CD4 T helper cell fates by different Notch ligands on antigen-presenting cells. Cell 117, 515–526 (2004). [PubMed]
  • Rutz S., Mordmuller B., Sakano S. & Scheffold A. Notch ligands Delta-like1, Delta-like4 and Jagged1 differentially regulate activation of peripheral T helper cells. Eur. J Immunol 35, 2443–2451 (2005). [PubMed]
  • Kang J. H. et al. . Gamma-secretase inhibitor reduces allergic pulmonary inflammation by modulating Th1 and Th2 responses. Am. J. Respir. Crit. Care Med. 179, 875–882 (2009). [PubMed]
  • Okamoto M. et al. . Jagged1 on dendritic cells and Notch on CD4+ T cells initiate lung allergic responsiveness by inducing IL-4 production. J Immunol 183, 2995–3003 (2009). [PubMed]
  • Okamoto M. et al. . Essential role of Notch signaling in effector memory CD8+ T cell-mediated airway hyperresponsiveness and inflammation. J. Exp. Med. 205, 1087–1097 (2008). [PMC free article] [PubMed]
  • Jurynczyk M., Jurewicz A., Raine C. S. & Selmaj K. Notch3 inhibition in myelin-reactive T cells down-regulates protein pinase Cq and attenuates experimental autoimmune encephalomyelitis. J Immunol 180, 2634–2640 (2008). [PubMed]
  • Hicks C. et al. . Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2. Nat Cell Biol 2, 515–520 (2000). [PubMed]
  • Yang L. T. et al. . Fringe glycosyltransferases differentially modulate Notch1 proteolysis induced by Delta1 and Jagged1. Mol. Biol. Cell 16, 927–942 (2005). [PMC free article] [PubMed]
  • Adler S. H. et al. . Notch signaling augments T cell responsiveness by enhancing CD25 expression. J Immunol 171, 2896–2903 (2003). [PubMed]
  • Krishnamoorthy N. et al. . Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med 14, 565–573 (2008). [PMC free article] [PubMed]
  • Sun J., Krawczyk C. J. & Pearce E. J. Suppression of Th2 cell development by Notch ligands Delta1 and Delta4. J Immunol 180, 1655–1661 (2008). [PMC free article] [PubMed]
  • Jang S., Schaller M., Berlin A. A. & Lukacs N. W. Notch ligand Delta-like 4 regulates development and pathogenesis of allergic airway responses by modulating IL-2 production and Th2 immunity. J Immunol 185, 5835–5844 (2010). [PMC free article] [PubMed]
  • Schaller M. A. et al. . Notch ligand Delta-like 4 regulates disease pathogenesis during respiratory viral infections by modulating Th2 cytokines. J. Exp. Med. 204, 2925–2934 (2007). [PMC free article] [PubMed]
  • Rutz S. et al. . Notch regulates IL-10 production by T helper 1 cells. Proc Natl. Acad. Sci USA 105, 3497–3502 (2008). [PubMed]
  • Bassil R. et al. . Notch ligand Delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development. J Immunol 187, 2322–2328 (2011). [PMC free article] [PubMed]
  • Billiard F. et al. . Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice. J. Exp. Med. 209, 1011–1028 (2012). [PMC free article] [PubMed]
  • Tran I. T. et al. . Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest 123, 1590–1604 (2013). [PMC free article] [PubMed]
  • Ng W. F. et al. . Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood 98, 2736–2744 (2001). [PubMed]
  • Ostroukhova M. et al. . Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-beta. J. Clin. Invest. 116, 996–1004 (2006). [PubMed]
  • Huang M. T. et al. . Regulatory T cells negatively regulate neovasculature of airway remodeling via DLL4-Notch signaling. J Immunol 183, 4745–4754 (2009). [PubMed]
  • Anastasi E. et al. . Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol 171, 4504–4511 (2003). [PubMed]
  • Yvon E. S. et al. . Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood 102, 3815–3821 (2003). [PubMed]
  • Kared H. et al. . Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through Notch signaling. Immunity 25, 823–834 (2006). [PubMed]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group